For Immediate Release� Actelion Shareholders to Receive $280 Per Actelion Share in All-Cash Tender Offer to be Launched by Johnson & Johnson and One Share of New R&D Company for Each Actelion Share as Stock Dividend Actelion R&D Unit to Spin Out into Standalone Company Based and Listed in Switzerland; New R&D Company to Continue Actelion's Successful Culture of Innovation and Johnson & Johnson to Hold Substantial Minority Interest Acquisition Expected to Accelerate Johnson & Johnson Revenue and Earnings Growth Rates; Immediately Accretive to Johnson & Johnson Adjusted Earnings Per Share Brings Actelion's Complementary Market-Leading Medicines and Promising Advanced Late-Stage Therapies to...
↧